NCT06465199View on ClinicalTrials.gov

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

289

Participants

Timeline

Start Date

October 14, 2025

Primary Completion Date

February 28, 2033

Study Completion Date

February 28, 2035

Conditions
Atypical Teratoid/Rhabdoid TumorNeuroblastoma RecurrentEmbryonal Tumor With Multilayered RosettesDIPG Brain TumorEwing SarcomaOsteosarcoma Recurrent
Interventions
DRUG

Eflornithine (DFMO)

Oral DFMO capsules

DRUG

AMXT 1501 Dicaprate

Capsule

Trial Locations (1)

17033

RECRUITING

Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey

Sponsors

Collaborators (1)

Aminex Therapeutics, Inc.
All Listed Sponsors
collaborator

Aminex Therapeutics, Inc.

INDUSTRY

collaborator

Penn State University

OTHER

lead

Milton S. Hershey Medical Center

OTHER